De Kock, Isabelle
Bos, Simon
Delrue, Louke
Van Welden, Sophie
Bunyard, Peter
Hindryckx, Pieter
De Vos, Martine
Villeirs, Geert
Laukens, Debby http://orcid.org/0000-0002-1984-5850
Funding for this research was provided by:
Bijzonder Onderzoeksfonds UGent (BOF20/PDO/047)
Article History
Received: 12 December 2022
Revised: 10 February 2023
Accepted: 17 February 2023
First Online: 18 April 2023
Declarations
:
: The scientific guarantor of this publication is Prof Dr Debby Laukens.
: Peter Bunyard is an employee of Redx Pharma Plc but had no control of the data nor control of information that might present a conflict of interest. The other authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.
: Dr Ellen Deschepper provided statistical advice for this manuscript and performed statistical analyses.One of the authors, Simon Bos, has significant statistical expertise.
: Written informed consent was waived because of the retrospective nature of the proof-of-concept study.
: The proof-of-concept study was approved by the Ethics Committee of Ghent University Hospital (EC/2018/1493, Belgian study registration number B670201838339). Approval from the institutional animal care committee was obtained.
: •Animal study: prospective; human proof-of-concept study: retrospective•Experimental•Performed at one institution